Targets for new anti-AML compounds.
| Target . | Relevant Compounds . |
|---|---|
| CD33 | Mylotarg, HuM195 +/- 131I, 90Y, 213Bi |
| CD45 | 131I-Anti-CD45 |
| MDR1/PGP | Cyclosporine, PSC 833 |
| Angiogenesis and/or VEGF | Thalidomide |
| SU5416 | |
| Anti-VEGF antibodies | |
| Hypermethylated chromatin | Decitabine |
| Histone deacetylase | Phenylbutryate trichostatin A, trapoxin |
| Bcl-2 | Bcl-2 antisense |
| S-phase checkpoint | UCN 01 |
| 20S proteasome | PS-341 |
| Tyrosine kinase (c-kit receptor) | STI 571 |
| Farnesyl transferase | BMS-214662, RH115777 |
| Target . | Relevant Compounds . |
|---|---|
| CD33 | Mylotarg, HuM195 +/- 131I, 90Y, 213Bi |
| CD45 | 131I-Anti-CD45 |
| MDR1/PGP | Cyclosporine, PSC 833 |
| Angiogenesis and/or VEGF | Thalidomide |
| SU5416 | |
| Anti-VEGF antibodies | |
| Hypermethylated chromatin | Decitabine |
| Histone deacetylase | Phenylbutryate trichostatin A, trapoxin |
| Bcl-2 | Bcl-2 antisense |
| S-phase checkpoint | UCN 01 |
| 20S proteasome | PS-341 |
| Tyrosine kinase (c-kit receptor) | STI 571 |
| Farnesyl transferase | BMS-214662, RH115777 |